Pre Formulation Studies Solubility & Stability Analysis - Part 2

Scientific concepts / discoveries / nature phenomena presented

• Pre-formulation studies for solubility and stability to predict:

  • in vivo absorption
  • bioavailability
  • pharmacological response

• Drug stability is necessary to prevent:

  • loss of potency/efficacy
  • formation of toxic degradation byproducts
  • deterioration outside and inside the body

• Drug–excipient interactions Excipients can change the drug’s stability and may promote:

  • degradation
  • physical/chemical changes

Types of stability (triggered by different factors)

• Therapeutic stability
• Physical stability
• Toxicological stability
• Microbiological stability
• Chemical stability

ICH stability guidance

• Stability testing follows ICH Q1A(R2), including forced degradation / forced stress stability.

Forced stress conditions (stress environments)

Used to trigger degradation via:

• pH
• temperature
• humidity / water activity
• light (visible/UV)
• oxidizing agents

Major degradation mechanisms

Explicitly listed degradation pathways include:

• Hydrolysis
  • ester hydrolysis → acid + alcohol
  • amide hydrolysis → acid + amine
• Isomerization
• Oxidation
  • oxygen-driven reactions
  • radical/peroxy radical chain reactions
• Polymerization and dimerization
• Solid-state phase transformation
• Dehydration and desolvation
• Cyclization
• Photolytic degradation
• Microbial degradation

Solid-state vs. liquid-state stability differences

• Solid formulations may be stable on the shelf, but in vivo they can:
  • solubilize
  • encounter different pH and chemical environments
• Solid-phase transitions and differing molecular states (e.g., ionized vs unionized) can alter reaction pathways.

Stability study rationale and outputs

Stability studies support:

• determining shelf life/expiration date for labeling
• defining storage conditions and packaging requirements
• assessing degradants and compatibility with excipients
• selecting the most suitable dosage form based on stability findings

---

Methodologies / study designs outlined

1) Pre-formulation stability objectives

• Ensure the drug substance and dosage form remain effective through shelf life
• Ensure safety by controlling/limiting degradation and harmful byproducts
• Map degradation risk under environmental factors, such as:
  • light
  • heat
  • moisture
  • pH
  • reacting species (excipients/analytes)

2) Forced stress stability study design (examples given)

• Prepare pre-weighed samples
• Store in stability chambers/cabinets under elevated stress conditions
• Example stress conditions:
  • 40°C, 60°C, 80°C
  • ambient temperature with high humidity
  • 40°C with 75% relative humidity
• Observe degradation up to 8 weeks
• Withdraw samples at 2, 4, and 8 weeks
• Compare stressed samples to:
  • properly stored (non-stressed) reference
  • freshly prepared reference
• Analyze degradation using:
  • stability-indicating assay, primarily reverse-phase HPLC
  • LC-MS to identify/characterize degradation products and degradants

3) Hydrolytic degradation stress approach

• Expose the drug to extremes using:
  • 0.1 N HCl
  • 0.1 N NaOH
• Duration mentioned: 8–12 hours (with refluxing noted)
• Identify hydrolysis patterns by functional class:
  • ester → acid + alcohol
  • amide → acid + amine

4) Photostability testing design

• Expose thin samples/layers to:
  • high-intensity light or UV in a photostability chamber
  • temperatures starting around 25°C, then increasing
• Use controls:
  • non-exposed samples, or
  • samples protected by light-impermeable materials
• ICH exposure targets stated:
  • 1.2 million lux-hours (visible light)
  • 200 Wh/m² (UV)
• Compare degradant formation versus fresh (reference) drug
• Liquid photostability for liquid dosage forms:
  • performed in aqueous and non-aqueous solvents

5) pH-dependent stability testing design

• Test across multiple pH values to model environments ranging from acidic to basic (e.g., physiological/formulation conditions)
• pH examples given: pH 1, 4, 7, 9
• Conditions mentioned:
  • often assessed at 37°C
  • duration example: 1 day to 1 month
• Withdraw samples at intervals and compare to fresh, non-exposed drug

6) Oxidative stability study concept

• Oxidation may occur through:
  • direct reaction with atmospheric oxygen
  • chain reactions via peroxy radicals
• More oxidation-prone features include:
  • unsaturated structures (double bonds)
  • oils/fatty acids
• Typical oxidative stress approach:
  • elevated temperature + oxygen (when structure suggests susceptibility)

7) Drug–excipient compatibility studies (solid and liquid)

Solid compatibility

• Use DSC to detect melting pattern changes
• Cross-validate with:
  • FTIR
  • Powder X-ray diffraction (PXRD)
  • SEM/TEM
  • HSM (as named in subtitles)
  • TLC and other analytical techniques
• If interactions occur:
  • the excipient may be rejected or
  • storage conditions may be adjusted

Liquid compatibility

• Assess in surrounding liquid media (examples):
  • ethanol, glycerin, water, sugar syrup, methanol
• Evaluate similar risks and mechanisms, including:
  • pH effects
  • oxidative/hydrolytic stability
  • ester stability and hydrolysis

---

Researchers / sources featured (named at end)

• ICH (International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use)
  • specifically ICH Q1A(R2)
• U.S. FDA (Food and Drug Administration)
• Indian FDA (as referenced generally)
• CPMP (Committee for Proprietary Medicinal Products; as referenced generally)
• WHO (World Health Organization)